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University School of Medicine, Nashville, Tennessee, USAc; The Broad Institute of Massachusetts Institute of Technology and Harvard University,
Cambridge, Massachusetts, USAd; Umeå Center for Microbial Research, Umeå University, Umeå, Swedene
ABSTRACT Chaperone-usher pathway (CUP) pili are extracellular organelles produced by Gram-negative bacteria that mediate
bacterial pathogenesis. Small-molecule inhibitors of CUP pili, termed pilicides, were rationally designed and shown to inhibit
type 1 or P piliation. Here, we show that pilicide ec240 decreased the levels of type 1, P, and S piliation. Transcriptomic and pro-
teomic analyses using the cystitis isolate UTI89 revealed that ec240 dysregulated CUP pili and decreased motility. Paradoxically,
the transcript levels of P and S pilus genes were increased during growth in ec240, even though the level of P and S piliation de-
creased. In contrast, the most downregulated transcripts after growth in ec240 were from the type 1 pilus genes. Type 1 pilus ex-
pression is controlled by inversion of the fimS promoter element, which can oscillate between phase on and phase off orienta-
tions. ec240 induced the fimS phase off orientation, and this effect was necessary for the majority of ec240’s inhibition of type 1
piliation. ec240 increased levels of the transcriptional regulators SfaB and PapB, which were shown to induce the fimS promoter
phase off orientation. Furthermore, the effect of ec240 on motility was abolished in the absence of the SfaB, PapB, SfaX, and
PapX regulators. In contrast to the effects of ec240, deletion of the type 1 pilus operon led to increased S and P piliation and mo-
tility. Thus, ec240 dysregulated several uropathogenic Escherichia coli (UPEC) virulence factors through different mechanisms
and independent of its effects on type 1 pilus biogenesis and may have potential as an antivirulence compound.
IMPORTANCE CUP pili and flagella play active roles in the pathogenesis of a variety of Gram-negative bacterial infections, includ-
ing urinary tract infections mediated by UPEC. These are extremely common infections that are often recurrent and increasingly
caused by antibiotic-resistant organisms. Preventing piliation and motility through altered regulation and assembly of these
important virulence factors could aid in the development of novel therapeutics. This study increases our understanding of the
regulation of these virulence factors, providing new avenues by which to target their expression.
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Although antibiotics have drastically reduced mortality causedby infectious diseases, we now face the spread of resistant
microorganisms, with epidemics of drug-resistant, as well as
multidrug- and pan-drug-resistant, pathogens (1). Additionally,
few new antibacterial drugs are currently in phase 2 or 3 clinical
trials (2), limiting future treatment options. Thus, new strategies
are needed to replace or augment current drug regimens and to
find treatments that do not inspire rapid resistance. One approach
is to develop antivirulence therapeutics that can treat disease, ei-
ther alone or in synergy with existing antibiotics. Bacterial attach-
ment is a critical initial step in the pathogenesis of many bacterial
infections that allows the colonization of specific niches in the
host. Antiadhesion therapeutics have been developed and shown
to effectively prevent and/or treat infections in animalmodels (3).
Here, we report on the antivirulence properties of compound
ec240. We found that ec240 prevents the production of several
types of pili that play critical roles in colonization and biofilm
formation by Gram-negative pathogens and simultaneously de-
creases their motility. Thus, we used this compound as a molecu-
lar scalpel to further dissect the complex circuitries that control
the expression and biogenesis of these important virulence fac-
tors.
One large family of adhesive organelles are pili assembled by
the chaperone-usher pathway, termed CUP pili. These pili are
critical virulence factors in a wide range of pathogenic bacteria,
including Escherichia coli, Klebsiella, Pseudomonas, Haemophilus,
Salmonella, and Yersinia (4). CUP pili mediate adhesion to host
and environmental surfaces, facilitate invasion of host tissues, and
promote interaction of bacteria with each other to form biofilms.
Each CUP gene cluster, organized in an operon, encodes pilin
subunits, a tip adhesin, and a dedicated chaperone and usher that
facilitate subunit folding and assembly. CUP pilin subunits have
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an N-terminal extension and an incomplete immunoglobulin-
like fold. Consequently, their folding requires their cognate
periplasmic chaperone, which is composed of two Ig-like domains
(5). The periplasmic chaperone binds to a pilin subunit, donating
a -strand to transiently complete the Ig fold of the subunit and
facilitate its proper folding (6). Chaperone-subunit complexes
then interact with their cognate outer membrane usher, which
forms a gated channel and catalyzes pilus assembly, wherein the
amino-terminal extension on each pilin subunit completes the Ig
fold of its predecessor in the pilus, noncovalently linking pilin
subunits together (7).
A recent analysis identified 458 CUP operons of 38 distinct
CUP pilus types based on usher phylogeny (8). Single Escherichia
genomes canhave asmany as 16 distinctCUPoperons (8). Among
the most studied of the CUP pili are the type 1, P, and S pili, each
of which is often encoded by strains of uropathogenic E. coli
(UPEC) and is associated with the ability of UPEC to establish
urinary tract infections (UTIs) (9–11). Type 1 pili encoded by the
fim operon are required for virulence in a murine cystitis model
(9). The type 1 pilus tip adhesin FimH binds mannosylated glyco-
proteins expressed on the luminal epithelial surface of human and
murine bladders, and this interaction facilitates bacterial coloni-
zation and invasion of bladder epithelial cells (12, 13). Upon in-
ternalization, UPEC can be expelled by innate defenses or escape
into the host cell cytoplasm, where it can replicate into biofilm-
like intracellular bacterial communities (IBCs), composed of ~104
cells, in a process dependent on type 1 pili (14–16). Although
discovered in murine models of cystitis, IBCs have also been
found in the urine of patients with UTIs (17). Thus, understand-
ing type 1 pilus biology andhow it is linked by regulatory cross talk
with other CUP operons will further our understanding of clinical
UPEC pathogenesis.
The UPEC genome typically contains 5 to 10 different com-
plete CUP operons; however, a single UPEC cell usually expresses
only one type of CUP pilus at a time (18). This suggests that UPEC
strains with multiple CUP operons also possess intricate genetic
circuitries that control the expression of CUP pili. Furthermore,
pili are energetically expensive to produce and can be immunos-
timulatory, necessitating regulation of their expression. Each of
the better-characterized UPEC CUP operons, type 1, P, and S pili,
encoded by the fim, pap, and sfa operons, respectively, is phase
variable. Phase variation is a very common mechanism of viru-
lence factor regulation in many bacterial species (19). Phase vari-
ation of the fim operon encoding type 1 pili depends on the re-
combinases FimB, FimE, and FimX. These recombinases can
cleave the genome at 9-bp inverted repeat sequences flanking the
fimS promoter, resulting in reorientation of the fimS promoter
region into the phase onor off position (20–23). Phase variation of
P and S pili does not involve chromosome rearrangement but
rather depends on differential regulator binding and Dam meth-
ylation of the respective promoter regions (24, 25).
There is also cross regulation betweenCUPoperons coordinat-
ing the expression of different CUP pili and flagella. Many regu-
lators are involved in the control of type 1, P, and S pilus expres-
sion. Both P and type 1 pili are regulated by Lrp, HNS, IHF, and
Crp, and type 1, P, and S pili are all regulated by Lrp and Dam
(24–27). It has also been shown that the CUP regulators PapB,
which controls P pilus (pap) expression, SfaB, which controls S
pilus (sfa) expression, and SfaX, another regulator in the sfa
operon, decrease the expression of type 1 pili (28–30). Type 1 pilus
expression has also been shown to alter other CUPs. A phase
locked on fim mutant, in which the fimS promoter cannot be
reoriented into the off position, was shown to have decreased pap
expression and motility (31, 32). Furthermore, SfaX and its ho-
mologue in the pap operon, PapX, were shown to decrease motil-
ity (30, 33). Thus, UPEC has complex networks coordinating the
expression of these CUP pili and flagella.
Using our in-depth knowledge of CUP pilus assembly and the
crystal structures of CUP chaperones and ushers, we have ratio-
nally designed compounds that block piliation. These small mol-
ecules, termed pilicides, have a ring-fused 2-pyridone backbone.
Pyridone pilicideswere initially designed to disrupt pilus assembly
by preventing chaperone-subunit-usher interactions. Previously
characterized compounds have been shown to bind to chaperones
in a conserved hydrophobic domain known to interact with the
usher, thus blocking pilus assembly by disrupting chaperone-
subunit-usher interactions (34). UPEC grown with pilicides were
significantly attenuated in (i) the ability to form type 1 pilus-
dependent biofilms, (ii) their adherence to bladder epithelial cells
in vitro, and (iii) their pathogenesis in amurine cystitis model (35,
36). Medicinal chemistry and the development of new synthetic
methodologies have resulted in a new class of pilicide with a
FIG 1 Pilicide ec240 affects type 1 pili. (A) Structure of ec240. (B) Growth curve of UTI89 in LB, LB-DMSO, or LB-250 M ec240. There is no significant
difference in the final bacterial density under these conditions, as measured by Kruskal-Wallis test. (C) Type 1 piliation in UTI89 grown with DMSO or ec240 as
measured by HA. Titers measured with no mannose and which are abrogated in the presence of mannose indicate agglutination mediated by type 1 pili. Titers
in the presence ofmannose indicatemannose-resistant or non-type-1-pilus-mediated agglutination. Error bars represent standard errors of themeans. Averages
shown are from at least three biological replicates.
Greene et al.

















smaller substituent in position 8 (Fig. 1A, e.g., cyclopropyl group)
in combination with a substituent in position 2 (e.g., aryl group)
in the central fragment (37–40). These compounds were charac-
terized for the ability to inhibit type 1 pilus-dependent biofilms or
the production of type 1 or P piliation on the cell surface (35–37,
40–42). A pilicide of this class, ec240 (Fig. 1A), is the most potent
inhibitor of type 1 piliation to date, as assessed by hemagglutina-
tion assay (HA) (37, 40), and a very potent inhibitor of type 1
pilus-dependent biofilm formation, with a 50% inhibitory con-
centration of 7 M (37).
In this study, we investigated the effects of ec240 on prototypic
UPEC strain UTI89, a cystitis isolate encoding 10 different CUP
operons (43). RNA sequencing (RNA-Seq) and analyses with iso-
baric tags for relative and absolute quantification (iTRAQ) re-
vealed that the most significant changes in the transcriptome and
proteome in response to ec240 were related to CUP pilus expres-
sion. We discovered that growth in ec240 decreased type 1 pilia-
tion by affecting the phase variation of the fimS promoter, result-
ing in the phase off state and abolishing fim expression. This
impact on the phase state likely contributed to the potency with
which ec240 inhibits type 1 pili. Furthermore, transcriptional pro-
filing revealed that ec240 increased the transcript levels of other
CUP operons, specifically, those encoding S and P pili, and that
this effect was independent of ec240 disruption of type 1 pilus
expression. Interestingly, despite increased S and P pilus subunit
transcript levels, ec240 prevents S and P piliation on the cell sur-
face, indicating that ec240 posttranscriptionally blocks S and P
pilus assembly. Thus, while ec240 blocks the assembly of S and P
pili posttranscriptionally, possibly through a mechanism de-
scribed for other pilicides, ec240 is also able to disrupt type 1 pilus
regulation by inducing the fimS phase off state, increasing its abil-
ity to inhibit type 1 pili. We also discovered additional virulence
pathways disrupted or affected by ec240, including decreasedmo-
tility and altered siderophore synthesis. As ec240 disruptsmultiple
virulence pathways, it is a promising lead compound for develop-
ment as an antivirulence therapeutic. Further investigation of its
impact on the virulence of other Gram-negative pathogens could
also be fruitful. This study also highlights the necessity of fully
characterizing the global impact of bioactive small molecules on
their target’s biology, as potential therapeutics can have unpre-
dicted effects, some of which may be therapeutically beneficial,
while others may be detrimental.
RESULTS
ec240 disrupts type 1 pilus production. Here we analyzed the
effects of the ring-fused 2-pyridone pilicide ec240 on UTI89 biol-
ogy in general and on CUP expression in particular. ec240
(Fig. 1A)was not toxic toUPEC, causing only a slight lag in growth
and not altering the final bacterial culture density (Fig. 1B). In
addition to inhibiting type 1 pilus-dependent biofilms, ec240 in-
hibited the maturation of type 1 pilus-dependent biofilms when
administered during biofilm formation (see Fig. S1 in the supple-
mental material). ec240 was also themost potent pilicide at inhib-
iting type 1 piliation, as quantified by HA (37, 40). In an HA,
normalized bacteria are serially 2-fold diluted and the titer indi-
cates the maximum dilution still capable of agglutinating guinea
pig erythrocytes.Mannose acts as a competitive inhibitor of type 1
pilus-mediated adhesion; thus, when the HA is performed in the
presence of mannose, agglutination by type 1 pili is prevented.
UTI89 showed anHA titer of 28when therewas nomannose in the
assay but a titer of 21 when mannose was present (Fig. 1C); there-
fore, UTI89 demonstrated a mannose-sensitive HA (MSHA) titer
of 28. After growth in 250 M ec240, UTI89 exhibited an MSHA
titer of 23 (Fig. 1C), indicating that growth in ec240 greatly de-
creased type 1 piliation on the cell surface. Lower doses of ec240
were also able to decrease type 1 piliation and theMSHA titer (see
Fig. S2 in the supplemental material). The slight mannose-
resistantHA (MRHA) titer of 21 inUTI89 grownwith andwithout
ec240 may be indicative of another pilus being expressed under
these conditions but at the limit of detection. Thus, as the expres-
sion of type 1 pili is linked to that of other CUP pili, we investi-
gated the global impact of ec240 on UPEC biology.
Transcriptional and proteomic responses to ec240. We as-
sessed the transcriptional profile of UTI89 grown with 250 M
ec240 or a dimethyl sulfoxide (DMSO) vehicle control to investi-
gate the global effects of ec240 on UPEC biology. We utilized a
relatively high concentration of ec240 in order to detail all possible
“off-target” effects. RNA-Seq was conducted on triplicate biolog-
ical samples grown under type 1 pilus-inducing conditions. We
identified 52 gene transcripts that were altered 3-fold when
UTI89 was grown in ec240 rather than the DMSO vehicle control.
Of these 52 genes, 15 had decreased transcript levels and 37 had
increased transcript levels. The transcript levels of CUP pilus
genes were affected by the pilicide ec240, as were the transcript
levels of genes with a variety of different functions, including mo-
tility, siderophore synthesis and transport, metabolism, transla-
tion, gene regulation, and stress response (Fig. 2A). There were
also some hypothetical genes with dysregulated transcript levels
(Fig. 2A). As shown in the MA plot (a plot of the log2 of the ratio
of abundances of each transcript between the two conditions [M]
plotted against the average log2 of abundance of that transcript in
both conditions [A]), the pap and sfa genes encoding P and S pili
had the most upregulated transcript levels, while the fim and flg
genes encoding type 1 pili and flagella had the most downregu-
lated transcript levels (Fig. 2B), with fim transcripts downregu-
lated 8- to 17-fold, pap transcripts upregulated 4- to 49-fold, and
sfa transcripts upregulated 4- to 25-fold (Fig. 2C). Furthermore,
CUP operon genes cumulatively make up 46% of the genes dys-
regulated by3-fold but 76% of the genes dysregulated by10-
fold after growth in ec240. This indicates that under type 1 pilus-
inducing conditions, themajor effect of ec240 is the dysregulation
of CUP pili.
We also measured the global effects of ec240 on proteins by
conducting an iTRAQ analysis of UTI89 grown with DMSO or
250 M ec240 under the same conditions as used for RNA-Seq.
This allowed us to identify 83 proteins with significantly altered
abundance after growth in ec240 (50 proteins were increased and
33 proteins were decreased). By iTRAQ analysis, we identified
altered levels of CUP proteins, as well as proteins involved in a
variety of different functions (Fig. 2D). In regard to CUP proteins,
growth ofUTI89 in ec240 significantly decreased the expression of
the FimC chaperone, FimD usher, FimF subunit, and FimH ad-
hesin (Fig. 2E) and significantly increased the expression of the
SfaE chaperone, SfaF usher, SfaH adhesin, PapA subunit, PapD
chaperone, and PapG adhesin (Fig. 2E). Interestingly, as P pili can
only be depolymerized into PapA subunits by boiling the pilus
fibers in urea, the PapA detected by iTRAQ analysis likely repre-
sents the fraction of PapA that is in an unpolymerized state within
the cell. Thus, ec240 decreased the transcript levels and abundance
of Fim proteins but increased the transcript levels and abundance
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of the Pap and Sfa proteins. The effect of ec240 on P and S pilus
assembly on the cell surface is addressed below.
The RNA-Seq and iTRAQ analysis data confirmed that ec240
alters CUP pilus expression.We also found that UPEC physiology
in general was changed. Several proteins involved in amino acid
biosynthesis and degradation have altered expression in the RNA-
Seq and iTRAQ analyses. Furthermore, the 50S ribosomal genes
rpmJ and rpmE, had 4.5- and 4.1-fold increased transcript levels,
respectively, in the RNA-Seq analysis. Together, these changes
could indicate an altered efficiency of mRNA translation and pro-
FIG 2 Global transcriptional and proteomic responses to ec240. (A)Genes whose expression is dysregulated by growth in ec240 rather thanDMSO, as identified
by RNA-Seq analysis. Genes were classified by using KEGG (http://www.genome.jp/kegg/) and EcoCyc (http://www.ecocyc.org). The genes in each functional
category are shown as percentages of the total genes dysregulated. (B) MA plots of UTI89 gene abundance following treatment with ec240. Each dot represents
an annotated UTI89 gene with the log2 of its relative abundance in ec240 versus that in DMSO (M) plotted against the average log2 of its abundance under both
conditions (A).M andA values are based on data from three biological replicates under each growth condition. The dotted lines indicate 3-fold changes. (C) Fold
changes in CUP gene transcripts altered in UTI89 grownwith ec240 rather than the DMSO vehicle control, as determined by RNA-Seq. Genes are shown in their
order within the operon. (D) Proteins dysregulated after growth in ec240 rather than DMSO, as determined by iTRAQ analysis. Proteins were classified by using
KEGG (http://www.genome.jp/kegg/) and EcoCyc (http://www.ecocyc.org). The proteins in each functional category are shown as percentages of the total
proteins dysregulated and include proteinswith increased anddecreased abundances. (E) Fold changes inCUPproteins altered inUTI89 grownwith ec240 rather
than the DMSO vehicle control, as determined by iTRAQ analysis. (F) Dysregulation by ec240 of siderophore-related and iron transport genes by both RNA-Seq
and iTRAQ analysis. Shown are fold changes in transcript or protein levels in UTI89 grown in ec240 rather than DMSO. Genes are shown in their order within
the operon.
Greene et al.

















tein production in response to growth in 250 M ec240. We also
discovered that ec240 altered iron regulation. ec240 increased the
transcript and protein abundance of several siderophore synthesis
genes, including proteins for yersiniabactin synthesis and uptake
(YbtESQTU, Irp1, and Irp2), as well as the enterochelin synthesis
protein Fès and the iron transporter proteins SitAB (Fig. 2F), in-
dicating that ec240 affects more than one iron uptake system. We
have shown by quantitative real-time PCR (qPCR) that sidero-
phore synthesis gene transcripts are increased 2-fold in
UTI89fim grown with ec240 rather than DMSO, indicating that
the effects of ec240 on siderophore expression are probably inde-
pendent of its disruption of fim expression. Finally, the RNA-Seq
and iTRAQ analyses demonstrated decreased expression of many
flagellar and chemotaxis genes, an effect of ec240 further discussed
below.
ec240 alters CUP pilus expression. RNA-Seq analysis demon-
strated that ec240 alters fim, sfa, and pap transcript levels. How-
ever, theUTI89 genome encodes 10CUPpilus operons,most with
unknown functions. We therefore measured the transcript levels
of subunit genes encoded at the 5= end of each of these CUP oper-
ons as surrogates for the overall expression of the operon. Using
qPCR, we confirmed that growth in ec240 decreased fimI tran-
script levels but increased papA and sfaA CUP subunit transcript
levels inUTI89 (Fig. 3A).However, the subunit transcript levels of
the other 7 CUP operons in UTI89 (f17-like, fml, auf, yad, yeh, yfc,
yqi) showed no significant changes after growth in pilicide, con-
firming the RNA-Seq results (Fig. 3A). The effect of ec240 on these
systemswas also confirmedby immunoblot assayswith antibodies
against the FimAmajor pilin, and theCUP chaperones FimC, SfaE
and PapD. Growth of UTI89 in ec240 decreased FimA and FimC
levels, while the levels of the PapD and SfaE chaperones were in-
creased (Fig. 3B), further confirming the iTRAQanalysis data. The
anti-FimA antibody also recognizes SfaA pilin, which can be dis-
tinguished from FimA by its smaller size. Thus, in the anti-FimA
immunoblot assay, we found that even though sfaA subunit tran-
script levels and SfaE chaperone levels were increased by ec240,
SfaA subunits were barely detectable (Fig. 3B). Thus, ec240 either
blocked sfaA translation or more likely blocked S pilus assembly
by inhibiting chaperone-subunit interactions, resulting in SfaA
degradation. Interestingly, while ec240 was identified as an inhib-
itor of type 1 pili, it more broadly impacted CUP pili, dysregulat-
ing type 1, P, and S pili. Surprisingly, it had divergent effects on
these homologous systems.
Disrupted fim expression alters the expression of the other
CUP pili. CUP pili are known to cross regulate each other. To
investigate if the effects of ec240 on CUP pili were a direct conse-
quence of its ability to disrupt fim expression, we deleted the fim
operon and used qPCR to quantify the expression of the other
nine CUP operons in UTI89fim, i.e., sfa, pap, auf, fml, f17-like,
yad, yeh, yfc, and yqi. We found that sfaA, papA, and f17-like pilus
subunit transcript levels were2-fold higher in UTI89fim than
in UTI89 after growth under type 1 pilus-inducing conditions
(Fig. 4A). In order to quantify pilus production, we harvested pili
fromUTI89 and UTI89fim. Pilus preparations were depolymer-
ized by boiling in urea and acid, and then individual pilin subunits
were resolved by SDS-PAGE. Amino-terminal sequencing of the
resolved major pilin subunits demonstrated that after growth un-
der type 1 pilus-inducing conditions, UTI89 produced FimA, the
type 1 pilus major subunit (Fig. 4B). Under the same conditions,
UTI89fim produced PapA, themajor subunit of P pili, and SfaA,
the major subunit of S pili (Fig. 4B), confirming the qPCR results.
However, we did not identify any f17-like pilin subunits. This
could indicate that the f17-like pilin subunits were not translated,
not polymerized into pili, or not harvested or resolved by this
method. The Amino-terminal sequencing results indicated that
the expression and assembly of other pili, specifically, S and P pili,
were induced in UTI89fim, identifying new regulatory connec-
tions coordinating the expression of UPEC CUP pili.
HA titers were used to quantify CUP piliation. We found that,
in contrast to UTI89, after growth under type 1 pilus-inducing
conditions, the UTI89fim mutant produced HA titers of 23.5 in
the presence or absence of mannose (Fig. 4C), mirroring what has
been shown for a conditional fim depletion strain (15). As FimH
binds mannose, soluble mannose prevents erythrocyte agglutina-
tion by type 1 pili and therefore decreases HA titers mediated by
type 1 pili. Thus, the fim operon deletion in the UTI89fim mu-
tant resulted in the induction of amannose-resistant pilus. On the
basis of the increased sfa and pap expression in UTI89fim
FIG 3 Pilicide ec240 alters CUP pilus expression. (A) qPCR of CUP pilin subunit transcripts in UTI89 grown with ec240. One subunit was used as a readout for
the overall transcript level of the operon. Shown is a log transformof the fold change in the transcript level inUTI89 grownwith ec240 compared toUTI89 grown
with DMSO. Error bars represent standard errors of themeans. Averages shown are from at least three biological replicates. Dotted lines indicates 2-fold changes
in the transcript level for the qPCRdata. (B) Immunoblot assay of CUP levels inUTI89 grownwithDMSOor ec240. Antibodies against type 1 pili identified FimA
and SfaA bands, while antibodies against PapD and SfaE identified PapD and SfaE, respectively.
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(Fig. 4A and B) and the fact that P pili do not bind to guinea pig
erythrocytes, we hypothesized that the mannose-resistant pili on
the UTI89fim mutant cell surface were S pili. Furthermore,
UTI89sfa, which is unable to produce S pili, lacks the lowMRHA
titer usually seen in UTI89 after growth under type 1 pilus-
inducing conditions (Fig. 4C). Deletion of the sfa operon, creating
UTI89fim-sfa, completely abolished the MRHA titer observed
in the UTI89fim mutant (Fig. 4C). The S pilus adhesin, SfaH,
binds to sialic acid (44). To further confirm that theMRHA titer of
UTI89fim was mediated by S pili, we enzymatically removed
sialic acid from the surface of the guinea pig erythrocytes used in
the assay (44). The MRHA titer observed in the UTI89fim mu-
tant was abolished upon removal of the sialic acid receptor from
the erythrocyte surface, while desialylation had no effect onUTI89
MSHA titers (Fig. 4C). These data confirmed that during growth
under type 1 pilus-inducing conditions, deletion of the fim operon
induces sfa expression and assembly of S pili in UTI89. Further-
more, HA titers of UTI89fim provide an assay for quantifying S
piliation.
Induction of CUP genes by ec240 is independent of its effects
on fim gene expression. Because S and P pilus subunit transcript
levels are increased in UTI89fim, we investigated whether the
ec240 effects on S and P subunit transcript levels were due to
decreased fim expression. Interestingly, qPCR revealed a pro-
nounced increase in the transcript levels of sfaA and papA in
UTI89fim in response to growth in ec240, relative to their levels
in UTI89fim grown with DMSO, the vehicle control (Fig. 4D).
ec240 did not significantly alter the transcript levels of the other
CUPoperons inUTI89fim. Therefore, although ec240 decreased
the fim transcript level, ec240 increased pap and sfa subunit tran-
script levels independent of its effects on fim expression.
Pilicide ec240 blocks CUP piliation. Although some of the
original pilicides decreased P piliation, ec240 was selected on the
basis of its ability to inhibit type 1 piliation and actually increased
the transcript levels of the sfa and pap operons. This could limit
the efficacy of ec240; it is not ideal to abolish one virulence factor
while inducing other virulence factors. Therefore, we further in-
vestigated the effects of ec240 on S piliation by determining the
HA titers of UTI89fim, which produces S pili. After growth of
UTI89fim with ec240, we discovered greatly decreased MRHA
titers (Fig. 5A), demonstrating that ec240 disrupted S pilus assem-
bly, despite the increased sfaA transcript level observed after
growth in ec240 (Fig. 4D and 5A).
To test the effects of ec240 on P pilus assembly and piliation
on the cell surface, we used the plasmid pFJ29 (45). UTI89 en-
codes a PapGIII adhesin that does not bind to human or guinea
pig erythrocytes. However, pFJ29 encodes an isopropyl--D-
thiogalactopyranoside-inducible pap operon from UPEC strain
J96, which has a PapGI adhesin that binds to human erythrocytes.
Using pFJ29, we demonstrated that ec240 decreased P piliation
2-fold, as measured by HA titer (Fig. 5B). Furthermore, there was
a 50% decrease in PapA protein present after growth in ec240,
while the levels of PapD chaperone remained constant, as deter-
mined by immunoblotting of whole-cell extracts with anti-PapA
and anti-PapD antibodies (Fig. 5C).We propose that ec240 blocks
P pilus assembly posttranscriptionally, leading to degradation and
FIG 4 CUP pilus response to fimmutation. (A) qPCR of each CUP pilin subunit transcript in UTI89fim as a readout of the overall transcript level of the CUP
operon. Shown is a log transform of the fold change in the transcript level in UTI89fim compared to UTI89. (B) Pili removed from the surface of UTI89 or
UTI89fim and depolymerized into pilin subunits were separated by SDS-PAGE and stained. Bands subjected to N-terminal sequencing are numbered, and the
CUP pilin subunits they contain are FimA (band 1), PapA (band 2), and SfaA (band 3). (C) Type 1 piliation in UTI89 and CUP operonmutants as measured by
HA titer and S piliation asmeasured byHA titer with desialylated guinea pig erythrocytes. (D) qPCRof eachCUPpilin subunit transcript inUTI89 orUTI89fim
grown with ec240 as a readout of the overall transcript level of the CUP operon. Shown as a log transform of the fold change in transcript levels in each strain
grown with ec240 compared to that strain grown with DMSO. Error bars represent standard errors of the means. Averages shown in are from at least three
biological replicates. The dotted lines in panels A and D indicate 2-fold changes in the transcript level for the qPCR data.
Greene et al.

















decreased PapA levels (Fig. 5B). This explains the discrepancy be-
tween the highly increased papA transcript levels and only mod-
erately increased PapA protein levels in UTI89 (Fig. 2) and indi-
cates how ec240 decreased P piliation in a cell actively transcribing
the pap operon (Fig. 5).
Mechanistic studies of ec240 action. Pilicides were originally
designed to bind to the pilus chaperone and prevent chaperone-
subunit-usher interactions to block proper pilus assembly (34).
Therefore, we analyzed the effect that deleting the fimC, sfaE, or
papD chaperone had on CUP expression, compared to the effects
of ec240. Loss of the cognate chaperone for a CUP operon should
prevent proper folding of the respective pilin subunits and their
assembly into CUP pili. Like UTI89fim, UTI89fimC exhibited
no MSHA but an MRHA titer of 24, with similar titers in the
presence and absence of mannose (Fig. 6A). The MSHA titer was
restored to wild-type levels by the expression of fimC in trans
(Fig. 6A). To further elucidate this defect, we examined fim ex-
pression. The fimS promoter element controlling the fim operon is
invertible and switches between the phase on and off orientations.
The phase state was quantified with a phase assay, by restriction
endonuclease digestion of the PCR-amplified fimS promoter re-
gion, which results in different-sizedDNA fragments correspond-
ing to the phase on or off state (20). After growth under type 1
pilus-inducing conditions (46), the majority of the UTI89 popu-
lation was in the fimS phase on position, while UTI89fimC re-
mained in the fimS phase off orientation and thus unable to ex-
press fim genes (Fig. 6B). Expression of fimC in trans in
UTI89fimC restored the phase on orientation (Fig. 6B). Thus,
successful pilus assembly is needed for cells to turn phase on.
However, the results for the P and S chaperonemutants were very
different. We observed no significant difference in papA or sfaA
subunit transcript levels between UTI89 and the UTI89papD or
UTI89sfaE chaperonemutant, respectively, after growthunder P
or S pilus-inducing conditions (see Fig. S3 in the supplemental
material). Thus, it is unlikely that ec240 induced increased pap or
sfa transcript levels because of disruption of PapD or SfaE chap-
erone function. However, it is possible that a chaperone from one
operon could complement the assembly defect of another operon,
allowing for pilus assembly even in thepapD orsfaE chaperone
mutants. This has been demonstrated for the PapD chaperone,
which can complement a fimC chaperone mutant (47). Thus,
although fim expression is sensitive to pilus assembly, it appears
that sfa and pap expression is not.
As mutation of the fimC chaperone altered the phase state and
pilicides were originally designed to interfere with FimC function,
we investigated if ec240 also affected the fimS phase orientation,
possibly by inhibiting FimC function. Using a phase assay, we
discovered that UTI89 grown in ec240 was fimS phase off, even
after growth under type 1 pilus-inducing conditions (Fig. 6C).
Lower concentrations of ec240 also induced the fimS phase off
orientation (see Fig. S2 in the supplemental material). Further-
more, ec240 had similar effects on the phase regardless of whether
the starting bacterial population was in the phase on or off orien-
tation. Thus, ec240 could both keep phase off cells in the phase off
orientation and switch phase on cells to the phase off orientation
(Fig. 6C).
We hypothesized that the ec240-induced fimS phase off orien-
tation was the result of disrupted chaperone function and pilus
assembly defects, with subsequent negative feedback on fimS, as
seen in UTI89fimC. Therefore, we analyzed the ability of ec240
to decrease type 1 piliation in a phase locked on mutant. This fim
phase locked on strain (LIR) has point mutations incorporated
into the fimS left inverted repeat, such that the Fim recombinases
can no longer reorient the fimS promoter (48). Surprisingly, ec240
had a minimal effect on type 1 piliation in the phase locked on
strain (Fig. 6E). This was not the case for all pilicides with activity
against type 1 pili. For example, pilicide ec342 decreased type 1
piliation in the phase locked on strain as well as in UTI89 (Fig. 6D
and E). With qPCR, we demonstrated that the phase locked on
strain produced the same level of fim subunit transcript after
growth in ec240 or DMSO, indicating that ec240 had no effect on
fimS promoter activity or transcript stability. Thus, it appeared
that ec240 minimally disrupts type 1 pilus assembly in the LIR
mutant and the effects of ec240 on type 1 piliation were primarily
due to its ability to induce the fimS promoter into the phase off
orientation. This effect on the fimS promoter could stem from
ec240 altering phase state regulators; however, it is also possible
that the small decrease inHA titer indicated a slight defect in FimC
chaperone function, which could impact the fimS phase orienta-
tion, as seen in the UTI89fimC mutant. Overall, the greater po-
tency with which ec240 inhibits type 1 piliation than other pili-
FIG 5 Pilicide ec240 alters CUP piliation. (A) Type 1 and S piliation as determined by HA titers. UTI89fim produces S pili; thus, the HA titer of UTI89fim
grown with ec240 demonstrates ec240-reduced S piliation. (B) HA with human erythrocytes performed with C600/pFJ29 (encoding the pap operon from J96)
grown alone or with DMSO or ec240. (C) ImageJ quantification of immunoblot assays quantifying PapA and PapD, shown as fold changes over C600/pFJ29.
Error bars represent standard errors of themeans. Averages shown are fromat least three biological replicates. Statistically significant differenceswere determined
by t test. *, P 0.05.
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cides do may stem from its ability to induce UTI89 into the fimS
phase off state, thereby preventing the expression of fim subunits.
The recombinases responsible for reorienting fimS between the
on and off states are encoded by fimB, fimE, and fimX. FimB and
FimX primarily turn the fimS promoter to the on orientation,
while FimE changes fimS to the off orientation (21, 22). Further-
more, many inputs affect the phase state through modulation of
recombinase expression or activity. Thus, we quantified recombi-
nase transcript levels after growth in ec240 and found that UTI89
had 2-fold lower fimB and fimE transcript levels (Fig. 6F). A
trend toward a decreased fimB transcript level was also observed in
UTI89fim grown with ec240 (Fig. 6F). Thus, the ability of ec240
to modulate the levels of the fimB and fimE recombinases may
result in the induction of the fimS phase off orientation.
The effects of ec240 on pap and sfa transcripts are independent
of fim disruption, as ec240 increased pap and sfa transcript levels
even in UTI89fim (Fig. 4D). fim expression impacts pap and sfa
expression, but pap and sfa expression alsomodifies fim phase and
expression. This CUP cross regulation occurs in part via PapB and
SfaB, which are pap and sfa transcriptional regulators encoded at
the beginning of their respective operons that can both induce the
off orientation of the fimS switch (28, 29). Furthermore, both
show significantly increased expression in UTI89 grown with
ec240 (see Fig. S4 in the supplemental material). papB is also in-
creased in UTI89fim after growth in ec240 (see Fig. S4). SfaX, a
regulator encoded at the end of the sfa operon, has also been
shown to turn UPEC phase off and to decrease transcription from
the fimS promoter (30). The SfaX homologue in the pap operon,
PapX, has not been shown to have the same effects on type 1 pili;
however, it shows some functional homology to SfaX, as both
decrease motility (33). Thus, increased expression of PapB, SfaB,
SfaX, and possibly PapX may explain the fimS phase off orienta-
tion and decreased fim expression observed in response to ec240.
To investigate if this is the sole mechanism of action of ec240, we
generated a deletion mutant strain, UTI89sfaX-papX-papB-
sfaB, lacking all four of these regulators. Treatment of
UTI89sfaX-papX-papB-sfaB with ec240 induced the fimS
phase off orientation (Fig. 6G). Thus, while ec240 may work in
part by inducing the regulators PapB, SfaB, and SfaX, which are
known to facilitate the off orientation of fimS, there exists an al-
ternative pathway by which ec240 carries out its mechanism of
action on type 1 pilus expression.
Pilicides alter flagellar expression and regulation. In addition
to affecting CUP pili, ec240 alters other virulence factors, includ-
ing motility. Flagella are an important virulence factor in many
Gram-negative bacteria, and they are important for UPEC patho-
genesis (49, 50). Flagella are large and complex surface organelles
that can be immunogenic and require significant energy to assem-
ble. Therefore, there is intricate regulation controlling flagellar
expression, with themaster regulator FlhDC stimulating the tran-
scription of class 2 genes for structural components and the regu-
lators FliA and FlgM controlling the class 3 structural components
FIG 6 Mechanism of action of pilicide ec240. (A) HA titer of UTI89 and the UTI89fimC chaperone mutant, alone and transformed with the pTRC99a vector
control or pfimC (pTRC99a-fimC). (B) Phase assay of UTI89 and the UTI89fimC chaperone mutant and each strain transformed with the pTRC99a vector
control or pfimC (pTRC99a-fimC) (seeMaterials andMethods). (C) Phase off or on UTI89 inoculumwas back diluted in LB, LB-DMSO, and LB-ec240. Shown
is a phase assay after growth of the back-diluted culture under type 1 pilus-inducing conditions. (D) Structure of ec342. (E) Piliation of UTI89 or LIR (fimS phase
locked on strain) grown under type 1 pilus-inducing conditions withDMSO, ec240, or ec342, asmeasured byHA. (F) qPCRof recombinase fimB, fimE, and fimX
transcript levels in UTI89 or UTI89fim grown with ec240, shown as the log transform of fold change in transcript levels in each strain grown with ec240
compared to each strain grownwith DMSO. (G) Phase assay of UTI89mutants after growth under type 1 pilus-inducing conditions, either alone or with DMSO
or ec240. Error bars represent standard errors of themeans. Averages shown in panels A, E, and F are from at least three biological replicates. Dotted lines indicate
2-fold changes in transcript levels for the qPCR data.
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(51). In CFT073, locking the fimS promoter phase off was previ-
ously shown to have no effect on motility, after growth under
motility-inducing conditions (31). However, here we demon-
strated that UTI89fim had greater motility (Fig. 7A) and greater
expression of fliC (Fig. 7B) than UTI89 after growth under type 1
pilus-inducing conditions. Thus, under conditions where UPEC
make type 1 pili, disruption of fim expression stimulates motility,
further indicating that type 1 pili and flagella are inversely regu-
lated, as well as controlled by environmental signals.
The inverse cross regulation of type 1 pilus and flagellum ex-
pression was decoupled by the pilicide ec240, which decreased the
expression of both fim and the flagellar structural genes from class
2 (flgBCDEF, fliF) and class 3 (fliC), as determined by RNA-Seq
analysis. We used qPCR to confirm the expression levels of flagel-
lar regulators and structural and chemotaxis genes in UTI89 and
found that ec240 decreased the transcript levels of these genes and
that it had a larger effect on the UTI89fimmutant (see Fig. S5 in
the supplemental material). Furthermore, immunoblot analysis
revealed decreased FliC after growth of UTI89 in ec240 (Fig. 7C).
Importantly, we also demonstrated that ec240 decreased UTI89
swimming motility in vivo (Fig. 7D). Thus, the pilicide ec240 is
able to decouple the regulation coordinating the expression of
type 1 pili and flagella in order to simultaneously decrease type 1
piliation and flagellarmotility.We hypothesized that the effects of
ec240 on motility might be due to increased expression of SfaX
and PapX, which are known to decrease motility (30, 33). Growth
of UTI89sfaX-papX in ec240 no longer significantly decreased
motility compared to that in the DMSO control, although a slight
reduction remained (Fig. 7D). However, ec240 had no effect on
the motility of UTI89sfaX-papX-papB-sfaB (Fig. 7D).
Therefore, deletion of sfaB and papB in the context of sfaX and
papX deletion abolished the activity of ec240 onmotility, suggest-
ing a possible role for SfaB and PapB in the control of motility in
response to ec240.
DISCUSSION
CUPpili are a diverse group of extracellular adhesive fibers assem-
bled by the chaperone-usher pathway that contain different ad-
hesins that bind to different receptors with stereochemical speci-
ficity andmediate attachment, invasion, and biofilm formation in
a variety of niches and host tissues. Many Gram-negative bacteria
encode multiple CUP pili, and many of these pili are disease asso-
ciated. The genome of the clinical isolate UTI89 carries 10 CUP
pilus operons (43). These include type 1, P, and S pili, which are all
associated with the ability of UPEC to establish UTIs (9–11). Ad-
ditionally, S pili are associated with neonatal meningitis (52).
Small molecules targeting CUP pili have the potential to be devel-
oped into therapeutics for the possible treatment and/or preven-
tion of bacterial infections such as UTIs (3, 35). Pilicides are low-
molecular-weight compounds that were designed to block
piliation. The pilicide ec240 was identified as a potent inhibitor of
type 1 pili; however, it was not known whether ec240 has broad-
spectrum activity against other CUP pili or how it might affect the
expression of other virulence factors. Thus, in this work, we char-
acterized the activity of ec240 onCUP expression inUTI89 and its
effects on other virulence traits of the organism. Our analysis of
ec240 provided important insights into how such antivirulence
molecules can short circuit genetic pathways controlling the ex-
pression ofmultiple virulence factors, thus revealing antivirulence
properties beyond inhibition of the expression of a specific CUP
pilus. Further, this analysis has demonstrated how antivirulence
therapeutics can serve as molecular scalpels to further dissect the
molecular networks interconnecting virulence factor expression.
CUP pili have complex regulation coordinating their expres-
sion. Type 1 pilus phase switching is mediated by the recombi-
nases FimB, FimE, and FimX (22, 23), but numerous environ-
mental signals and regulators affect the phase switching rates of
the fimS promoter and promoter activity when fimS is in the phase
on orientation (24, 26, 30, 53, 54). We have now demonstrated
that the fimS phase state and fim expression are also sensitive to
successful pilus assembly. Furthermore, there are extensive net-
works that interconnect CUP pili with the control of other viru-
lence factors, especially flagella. Bacteria alternate between the
production of pili to colonize a specific environment and the pro-
duction of flagella to swim to new environments and therefore
need regulatory circuits to accomplish these lifestyle choices. For
FIG 7 Effects of pilicide ec240 on motility. (A) Swimming motility in soft agar of UTI89fim as determined by the fold change in the diameter of the growth
zone compared to that of UTI89 after the growth of each strain under type 1 pilus-inducing conditions. (B) qPCR of fliC transcript levels in UTI89fim, shown
as a log transform of the fold change relative to UTI89 after growth under type 1 pilus-inducing conditions. (C) Immunoblot assay of flagellar levels in UTI89
grownwithDMSOand ec240with anti-H7 antibody. (D) Swimmingmotility in soft agar ofUTI89 orUTI89mutants grownwith ec240 as determined by the fold
change in the diameter of the growth zone compared to that of UTI89 or UTI89 mutants grown with the DMSO vehicle control. *, P  0.05. Statistically
significant differenceswere determined by one-sample t test. Error bars represent standard errors of themeans. The dotted lines in panel B indicate 2-fold changes
in transcript levels for the qPCR data.
Pilicide ec240 Disrupts Virulence Circuits in UPEC

















example, type 1 pili, encoded by the fim operon, have phase-
variable expression mediated by the inversion of its promoter el-
ement (20). It has been shown that a phase on fimmutant ofUPEC
strain CFT073 has decreased P pilus transcripts and flagellar ex-
pression (31, 32). Furthermore, several regulators in the S and P
operons decrease the expression of type 1 pili and flagella (28–30,
33), thus coordinating the types of extracellular appendages that
are expressed by a cell at a given time. The presence of redundant
regulators to coordinate the production of different CUP pili and
flagella indicates the necessity of producing these virulence factors
only in specific niches and host tissues. Here we present evidence
of additional regulatory circuitries interconnecting the expression
of type 1 pili with other CUP pili and flagella. We discovered that
UTI89fim has increased pap, sfa, f17-like, and fliC transcript lev-
els and increased flagella and S and P pili on the cell surface. CUP
pili are known to mediate tissue tropisms through binding to dif-
ferent receptors, and thus, such a compensatory response could
increase UPEC fitness by allowing it to bind to other receptors
found in that environment or enabling some of the population to
colonize new niches or host tissues.
The pilicide ec240was designed to prevent CUPpilus assembly
and was found to decrease type 1 pilus-dependent biofilm forma-
tion (36). ec240 is one of the most potent pilicides described to
date at inhibiting type 1 piliation as measured by HA titers. We
found that ec240 results in the fimS promoter adopting the phase
off orientation, thus preventing the transcription of fim genes
(Fig. 8). Since ec240 has aminimal effect on type 1 pilus biogenesis
in the fimS phase locked on mutant, we argue that it works pri-
marily by inducing the phase off orientation of the fimS promoter
switch, whichmay explain its greater potency than other pyridone
compounds. The fimS phase off orientation may stem from slight
defects in FimC chaperone function or could be due to the effects
of ec240 on fim regulators. Growth in ec240 increased the expres-
sion of several negative regulators of type 1 pili, SfaB, PapB, and
SfaX, which likely contribute to the ability of ec240 to turn UPEC
fimS phase off. However, growth of UTI89sfaX-papX-papB-
sfaB in ec240 resulted in the fimS phase off configuration, indi-
cating that ec240 may also impact other regulators of fim expres-
sion. It is also possible that ec240 controls the fimS phase state by
impacting both FimC chaperone function and the levels of phase
regulators. We are further investigating other pathways affected
by ec240 thatmay contribute to the fim phase effects. For example,
the global regulator Crp has been previously shown to be involved
in the control of the expression of type 1 and P pili (24, 26). We
find that type 1 pilus expression is decreased in a crp mutant;
however, ec240 does not alter the expression of type 1, P, or S pili
in the crp deletion mutant compared to that in the DMSO con-
trol, indicating that Crp may be involved in mediating ec240 con-
trol of CUP pili. If the effects of ec240 on fim are indeed mediated
by several redundant regulators, it should be more difficult for
UPEC to evolve resistance to the effects of ec240, increasing its
therapeutic potential.
Given the complex regulatory circuits coordinating CUP pilus
and flagellum expression, we used RNA-Seq and iTRAQ to ana-
lyze the global effects of ec240 on wild-type UTI89 and
UTI89fim. These analyses revealed that ec240 dysregulated a va-
riety of biological processes. The largest changes induced by ec240
in UTI89 were dysregulation of CUP pili and flagella, specifically,
increased expression of S and P pili and decreased expression of
type 1 pili and flagella. Additionally, ec240 was found to impact
iron regulation within the cell, including siderophore synthesis
genes and iron transporters. Iron is an essential element, and
UPEC produces a variety of iron-scavenging compounds called
siderophores to harvest iron from their environment. During the
formation of IBCs inside murine bladder host cells, UTI89 up-
regulates the expression of several siderophore synthesis genes
(55), further indicating their importance in UPECUTIs. It is pos-
sible that ec240 alters a regulator of siderophores or results in
decreased intracellular levels of iron. We are further investigating
this effect in order to fully understand the virulence profile exhib-
ited by UPEC after growth in ec240.We also clarified the effects of
ec240 on CUP pili. The increased S and P subunit transcript levels
were not due to disrupted fim expression, as we found that ec240
increased S and P subunit transcripts even in the UTI89fimmu-
tant. Thus, ec240 activates S and P transcript levels independent of
its effects on fim expression, and we are further investigating this
ec240 activity. Although no function other than inversion of the
fimS switch has been attributed to the recombinases, it would be
interesting to investigate if they have an impact on the expression
of other CUP pili, as seen for several other CUP regulatory pro-
teins.
ec240 prevents type 1, P, and S piliation, which is associated
with UTIs and other infections (9–11, 52). ec240 is very similar in
structure to the pilicide 5d, which was crystallized with the PapD
chaperone andwhich bound to a conserved hydrophobic patch on
the chaperone known to mediate chaperone-subunit-usher inter-
actions (36, 37). Thus, we propose that ec240 blocks S and P pilus
assembly, as demonstrated for other similar pilicides (36, 37),
(Fig. 8). However, ec240 controls the fimS phase state and there-
fore type 1 piliation. It is possible that ec240 induces a slight defect
in FimC chaperone function, which then impacts fimS orienta-
tion, or that ec240 controls fimS phase by altering the levels of
phase regulators. Overall, it appears that ec240 has different
mechanisms for inhibiting these homologous pili. The biological
impact of ec240 inhibition of all three of these UTI-associated pili
needs to be investigated in animal models of UTI to further eval-
uate the therapeutic potential of ec240.
In addition to the effects of ec240 on S and P pili, we demon-
strated that ec240 was able to disrupt the regulatory connections
between type 1 pili and flagella. Although flagellar expression is
induced in UTI89fim, where type 1 pili are not expressed, ec240
leads to decreased expression and production of both type 1 pili
and flagellar proteins. We have shown that growth in ec240 in-
FIG 8 Model of pilicide ec240 action on CUP pili and flagella.
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creased the expression of the P and S operons, which include PapX
and SfaX, regulators that are known to decrease motility (30, 33).
However, ec240 remained capable of inhibiting motility in
UTI89sfaX-papX and thus the effects on flagella were not me-
diated solely by the activity of PapX and SfaX. However, in
UTI89sfaX-papX-papB-sfaB, the effect of ec240 onmotility
was abolished, indicating a possible new role for SfaB and PapB in
motility regulation. The importance of all four of these regulators
in mediating the effects of ec240 on motility should decrease the
rate at which UPEC can evolve resistance to this compound, as
resistant mutants would need to have inactivated all four of these
regulators.
As important virulence factors, CUPpili are optimal targets for
antivirulence compound development, and several such thera-
peutics have been developed. The structure of the FimH adhesin
bound to mannose (36) has been used to rationally design mole-
cules, termed mannosides, that block FimH function by binding
in the FimH mannose-binding pocket. Mannosides are potent
inhibitors of biofilm formation in vitro and can prophylactically
prevent acute UTI and treat chronic UTI in a mouse model when
delivered orally (3). Furthermore, vaccines that stimulate an im-
mune response to pilus adhesins can protect against cystitis in
mouse models (56) and pyelonephritis in a primate model (57).
Unlike these other antivirulence therapeutics, pilicide ec240 can
simultaneously disrupt the production of type 1, P, and S pili, as
well as flagella. Thus, ec240 holds promise for the development of
a therapeutic for treatingUPECUTIs. As otherUPEC isolatesmay
have modified CUP regulatory pathways or different CUP pilus
structures, further studies are needed to determine if ec240 func-
tions similarly in other UPEC isolates. These pili are also involved
in a variety of other infections mediated by Gram-negative bacte-
ria, and future work will establish their efficacy against different
organisms. To develop this compound into a therapeutic, further
studies are needed to assess its pharmacokinetics and pharmaco-
dynamics and to determine the concentration at which it accumu-
lates in the bladder or other potential sites of infection. Manno-
sides are very different in structure from ec240, but it has been
shown that they are present in the urine of mice at100Mafter
oral or intraperitoneal dosing at 100 or 10 mg/kg, respectively,
indicating that it is possible for small molecules to be present in
the urine at these levels (3). Although most of the experiments
reported here were conducted at 250 M, we also observed some
of these phenotypes at lower concentrations of ec240 (see Fig. S2
in the supplemental material), so this compound could be thera-
peutically active even if it cannot reach 250 M at the site of
infection. Overall, molecules like ec240 could be therapeutically
beneficial and can be used as chemical probes to further dissect the
regulatory networks that fine-tune piliation and virulence factor
expression.
MATERIALS AND METHODS
Pilicides. Pilicides ec240 and ec342 were synthesized as previously de-
scribed (37, 39).
Bacterial strains. Mutant strains were constructed with the  Red
recombinase system (58). The strains used in this study are detailed in
Table S1 in the supplemental material.
Bacterial growth conditions. Unless otherwise stated, strains were
grown under type 1 pilus-inducing conditions, i.e., static incubation in
Luria broth (LB) at 37°C for 24 h and then subculturing at 1:1,000 in LB
for an additional 24-h static incubation at 37°C (2  24 h) (46). For P
pilus-inducing conditions, bacteria were grown on tryptic soy agar plates
at 37°C for 2 24 h (59). For S pilus-inducing conditions, bacteria were
grown on LB plates with 40 mM NaCl at 37°C (60). Growth was in the
pilicide at 250 M or in the DMSO vehicle control at 0.5%, unless other-
wise stated. Strains were grown in ampicillin at 100g/ml, where needed.
Swimming motility. Swimming motility was assessed after growth in
type 1 pili-inducing conditions by the diameter of growth in 12 ml of LB
0.25% agar in six-well plates.
Immunoblot analyses. UTI89 or isogenic mutants were grown under
type 1 pilus-inducing conditions with DMSO or 250 M ec240. Normal-
ized cells were processed for SDS-PAGE. Membranes were probed with
antisera for FimCH, FimA, PapD, SfaE, or H7 (BD-Difco) at 1:10,000.
RNA extraction and qPCR. qPCR for CUP transcript levels was
conducted with samples of UTI89 or isogenic deletion mutants grown
under type 1 pilus-inducing conditions. RNA was extracted from flash-
frozen bacterial cell pellets according to the manufacturer’s protocol
(Qiagen, ZymoResearch). RNAwas treated with TurboDNase (Ambion)
according to the manufacturer’s protocol and then tested for complete
removal of DNA by PCR with 16S or GyrA primers. RNA was reverse
transcribed with random primers (Invitrogen) and Superscript II reverse
transcriptase (Life Technologies). For qPCR, 100 ng of a cDNA or
RNA negative control that was not reverse transcribed was used as a tem-
plate for qPCRwith SYBR green according to themanufacturer’s protocol
(Bio-Rad). qPCR was conducted with primers specific to CUP subunit
genes or other target genes and the gyrA housekeeping gene. All primers
were validated for qPCR efficiency. Relative fold change was determined
by the Pfaffl method, where fold change  2CT target (control  sample)/
2CT ref (control  sample) (61). We used technical replicates for each gene
tested and at least three biological replicates for each experiment.
Generation of cDNA libraries for RNA-Seq. Triplicate UTI89 sam-
ples were grown under type 1 pilus-inducing conditions in the presence of
250Mec240 or the DMSO control. Total RNAwas isolated as described
above. Illumina cDNA libraries were generated by using a recently devel-
oped multiplexed library construction protocol called RNAtag-Seq (Al-
exander A. Shishikin et al., submitted for publication). Briefly, bar-coded
adapters were ligated directly to the total RNA, tagging each sample with
a unique sequence identifier. The bar-coded samples were then pooled,
and all subsequent steps of library construction were conducted with the
pool. These steps included (i) rRNAdepletionwith RiboZero (Epicenter),
(ii) first-strand cDNA synthesis with a primer complementary to a con-
stant region of the bar-coded adapter, (iii) ligation of an adaptor to the 3=
end of the cDNA, and (iv) PCR amplification of the cDNA with primers
fused to Illumina sequencing adapters. These libraries were sequenced
with the Illumina HiSeq 2000 sequencing system to generate 25 base
paired-end reads.
RNA-Seq analysis. Reads were aligned with the UTI89 chromosome
and pUTI89 (RefSeq NC_007946 and NC_007941, respectively) by using
BWA version 5.9 (62). Gene annotations were from RefSeq and Rfam
(63). The overall fragment coverage of genomic regions corresponding to
features such as open reading frames and rRNAs was conducted by using
bioinformatic pipelines developed in house as previously described (64).
Differential-expression analysis was conducted with DESeq (65).
Hemagglutination assays. Bacteria were grown under type 1 pilus-
inducing conditions in the presence of 250 M ec240 or the DMSO con-
trol. Pilus expression was assessed by HA as previously described (66) in
bacterial cultures normalized to an optical density at 600 nm (OD600) of 1
and guinea pig erythrocytes normalized to anOD640 of 2. The experiment
was conducted in parallel with phosphate-buffered saline (PBS)–4%
mannose. To quantify pilus binding to sialic acid, guinea pig erythrocytes
were enzymatically desialylated by incubation in neuraminidase fromAr-
throbacter ureafaciens (EY Labs) for 2 h at 37°C while rocking (44). The
erythrocytes were pelleted at 3,000 rpm, the enzymewas removed, and the
erythrocytes were resuspended in PBS to an OD640 of 2. P pilus HAs were
conducted after growth overnight at 37°C while shaking in LB with
250 M ec240 or the DMSO control. HAs were conducted with bacterial
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cultures normalized to anOD600 of 1 and human erythrocytes normalized
to an OD640 of 1.9.
Phase assays. Bacterial cells were grown under type 1 pilus-inducing
conditions in the presence of 250 M ec240 or the DMSO control. Phase
primers flanking the fimS promoter were used to PCR amplify the fimS
region of theUTI89 genome, the PCRproductwas digestedwithHinf1 for
2 h at 37°C, and then the DNA bands were resolved on a 2% agarose gel
(20). Band intensities were quantified by ImageJ.
Amino-terminal sequencing. Bacterial cultures of UTI89 or isogenic
mutants were grown under type 1 pilus-inducing conditions. One liter of
bacterial culture was pelleted by centrifugation at 8,100 rpm for 12min at
4°C, and the bacteria were resuspended in 25 ml of 4 mM Tris, pH 8. Pili
were removed from the cell surface by blending at speed 7 in an Omni-
mixer (Sorvall) for 2min, twice. The suspensionwas centrifuged at 16,000
 g, and the supernatant containing the pili was decanted and salt precip-
itated with 300 mM NaCl and 100 mM MgCl2. Pili were collected by
centrifugation at 21,000  g and resuspended in 1 mM Tris, pH 8. Pili
were depolymerized by boiling in 50 mM HCl and 4 M urea for 10 min
and then neutralized with 50 mM NaOH, subjected to SDS-PAGE to
separate pilin subunits, transferred to polyvinylidene difluoride, stained
with 1% Coomassie blue R-250 in 40% methanol, and destained in 50%
methanol. Subunit bands were excised, and protein identities were deter-
mined by N-terminal sequencing (Midwest Analytical Inc.).
Absolute quantitation of protein level differences by iTRAQ mass
spectrometry. UTI89 was grown under type 1 pilus-inducing conditions
in the presence of DMSO (vehicle) or 250 M ec240. Bacteria were pel-
leted by centrifugation at 6,000 rpm for 10min, and cells were acidified in
order to dissociate type 1 pilus subunits as described above. Bacteria were
mechanically disrupted in radioimmunoprecipitation assay buffer con-
tainingComplete protease inhibitor (EDTA free; Roche). Total cell lysates
were subjected to five pulses of sonication at a 20% amplitude (Sonic
Dismembrator; Fisher Scientific), followed by incubation with constant
rotation at 4°C for 2 h to solubilize membrane proteins. Insoluble cellular
debris was then removed by centrifugation atmaximum speed for 10min.
The total protein concentration of each sample was determined by bicin-
choninic acid assay (Pierce), and 100 g of total protein per sample was
processed for iTRAQmass spectrometry as previously described (67, 68),
with some modifications (see Text S1 in the supplemental material). Au-
tovalidationwas performed such that peptide assignments tomass spectra
were designated valid following an automated procedure during which
score thresholds were optimized separately for each precursor charge state
and the maximum target-decoy-based false-discovery rate (FDR) was set
to 1.0%. To obtain iTRAQprotein ratios, themedianwas calculated for all
of the peptides assigned to each protein. Frequency distribution histo-
grams for log2 protein ratios were obtained with GraphPad Prism 6.0.
Log2 ratios were then fitted to a normal distribution by least-squares re-
gression. The mean and standard deviation derived from the Gaussian fit
were used to calculate P values that were subsequently corrected for mul-
tiple comparisons by the Benjamini-Hochberg (BH) method (68). Pro-
teins with a BH FDR P value of 0.05 were defined as significantly
changed.
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